Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs TORM plc (TRMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs TORM plc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $223.95 (market cap $29.60B), while TORM plc trades at $28.9 (market cap $2.93B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 10.1× TORM plc's market cap, and TORM plc pays a 9.77% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | TRMD | |
|---|---|---|
Market Cap | $29.60B | $2.93B |
Sector | Health | Technology |
52-Week High | $491.22 | $34.87 |
52-Week Low | $205.48 | $18.77 |
Enterprise Value | $27.56B | $3.82B |
Dividend Yield | — | 9.77% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $222.54, up 2.56% today, amid a bearish technical signal with support at $218 and resistance at $223. The company reported strong revenue growth to $3.71B in 2025 and turned profitable with net income of $313.75M, though recent Q2 2026 earnings missed estimates. Analyst consensus remains bullish with a $370.07 price target, but multiple law firms are investigating potential securities fraud, creating near-term uncertainty.
The outlook is mixed: robust fundamentals and analyst support suggest long-term upside, but legal risks and recent earnings volatility pose significant headwinds. Investors face tension between strong profitability metrics and heightened sentiment risks from ongoing investigations.
TRMD trades at $28.84, down 1.2% with a bearish technical signal despite strong fundamentals. The company reported robust 2025 results with $1.34B revenue, $285.3M net income, and a 24.41% net margin. Recent earnings show mixed performance with Q2 2026 expectations at $3.41 EPS. Analyst consensus remains unanimously bullish with 3 buy ratings. Technical indicators show oversold conditions with RSI at 24.63, while support levels cluster around $28.
The stock presents a value opportunity with attractive valuation multiples (P/E 8.4, EV/EBITDA 5.95) and strong profitability metrics (ROE 15.62%). Near-term catalysts include Q2 2026 earnings and the $0.70 dividend payment in June. Key risks include earnings volatility, tanker market cyclicality, and negative cash flow trends. Institutional ownership stability and positive analyst coverage support the bullish case despite technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About TORM plc
TORM plc is one of the world's largest owners and operators of product tankers, specializing in the transportation of refined oil products like gasoline, jet fuel, and diesel. Operating under its integrated 'One TORM' model, the company maintains a modern, wholly-owned fleet of nearly 90 vessels. It is widely recognized by investors for its aggressive variable dividend policy, which returns a significant portion of its cash flow directly to shareholders during periods of high freight rates.
Read more on TRMD →
